Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00561834 · ClinicalTrials.gov registry record · Phase 1
Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00561834: Completed Phase 1 study, sponsored by University of Colorado, Denver.
NCT00561834 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00561834, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.
Primary Outcome
The mean change in best corrected Snellen visual acuity at 6 months in NAION patients treated as needed with ranibizumab.
Interventions
- DRUG ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
What the finished NCT00561834 record still lists
NCT00561834 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which ranibizumab is the first listed.
NCT00561834 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00561834 about?
NCT00561834 is a clinical study titled "Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy". The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.
What is the current status of trial NCT00561834?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2007-11. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00561834?
The interventions under investigation include: ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00561834?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00561834's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia